XLO Xilio Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why XLO matters now
Xilio Therapeutics, Inc. (XLO) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.10 with -1.09% on the session and $59.8M in market capitalization; recent performance reads 1-month +7.46% and YTD -1.90%.
The latest financial table shown here is Q1 2026, with revenue of $12.6M, net income of $-9.5M, and EPS of $-0.58. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -99.3%.
The latest indexable market news headline is "Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $98.00; recent insider activity includes Brennan Aoife filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
19.81
P/S
1.08
EV/EBITDA
2.87
DCF Value
$36.51
FCF Yield
-99.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.7%
Operating Margin
-79.0%
Net Margin
-58.5%
ROE
-117.2%
ROA
-19.1%
ROIC
-34.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.6M | $-9.5M | $-0.58 |
| Q4 2025 | $13.7M | $10.4M | $0.81 |
| FY 2025 | $43.8M | $-35.0M | $-4.19 |
| Q3 2025 | $19.1M | $-16.3M | $-1.54 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$98.00
Target (Median)
$98.00
Target Range
$98.00 - $98.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.09
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.